More Troubles For Martin Shkreli – That Guy Drug Makers Despise
Executive Summary
Martin Shkreli, who is largely despised by the biopharmaceutical industry, may be in even deeper trouble than he thought, with prosecutors telling a judge on May 3 they are considering additional charges against the former drug company CEO, who already is facing seven criminal counts, including securities fraud. Turing Pharmaceuticals Inc., one of the firms Shkreli created and used to lead, also is up against a new lawsuit from Impax Laboratories Inc., which is claiming breach of contract involving the drug Daraprim, whose price was hiked by more than 5,000%.
You may also be interested in...
Amgen's Harper Says Repatha Is Priced Right
The things that keep Sean Harper up at night have changed over the last few years as science has advanced and the drug development landscape has changed. Harper, who is the head of R&D at big biotech Amgen Inc., once worried that his company wouldn't be able to keep up, now he's concerned with where the money is going to come from.
It Was Shkreli's Show, But Pharma Was On Trial
The House Oversight and Government Reform Committee hearing on drug prices was the hottest spot in a very damp and cold Washington on Feb. 4 and former Turing Pharmaceutical Inc. CEO Martin Shkreli gave lawmakers and the overflow-crowd in attendance what they were anticipating: Several big smirky smiles, a lot of eye rolling and a refusal to testify – citing his "Act of Production Privilege" under the Fifth Amendment to the US Constitution at the advice of his counsel.
Shkreli's Price-Hike Brag: '$1bn Here We Come'
Excerpts from more than 300,000 documents, including emails, from Turing Pharmaceuticals Inc. and Valeant Pharmaceuticals International Inc. painted a picture that's anything but pretty about how those firms went about buying older drugs and jacking up their prices – with the now-former head of one of those companies, Martin Shkreli, declaring "$1bn here we come."